Collectively, these findings establish LCN2 as a pleiotropic mediator of neuroinflammatory pathogenesis across neurological disorders, positioning pharmacological modulation of LCN2 expression or ligand-receptor interactions as a therapeutic target for CNS conditions. This evidence concerns the gene LCN2 and nervous system disorder.